Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 442

1.

Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: A prospective study.

Joensuu H, Eriksson M, Collan J, Balk MH, Leyvraz S, Montemurro M.

Radiother Oncol. 2015 Jul 27. pii: S0167-8140(15)00379-5. doi: 10.1016/j.radonc.2015.07.025. [Epub ahead of print]

PMID:
26228971
2.

Physician Estimations of the Risk of Gastrointestinal Stromal Tumor Recurrence-Not Accurate Enough?: More Education May Be Needed.

Joensuu H.

JAMA Oncol. 2015 Jul 23. doi: 10.1001/jamaoncol.2015.2404. [Epub ahead of print] No abstract available.

PMID:
26203794
4.

Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion.

Tervonen TA, Belitškin D, Pant SM, Englund JI, Marques E, Ala-Hongisto H, Nevalaita L, Sihto H, Heikkilä P, Leidenius M, Hewitson K, Ramachandra M, Moilanen A, Joensuu H, Kovanen PE, Poso A, Klefström J.

Oncogene. 2015 Jul 13. doi: 10.1038/onc.2015.248. [Epub ahead of print]

PMID:
26165838
5.

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.

O'Sullivan CC, Bradbury I, Campbell C, Spielmann M, Perez EA, Joensuu H, Costantino JP, Delaloge S, Rastogi P, Zardavas D, Ballman KV, Holmes E, de Azambuja E, Piccart-Gebhart M, Zujewski JA, Gelber RD.

J Clin Oncol. 2015 Jun 22. pii: JCO.2015.60.8620. [Epub ahead of print]

PMID:
26101239
6.

Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion.

Maki RG, Blay JY, Demetri GD, Fletcher JA, Joensuu H, Martín-Broto J, Nishida T, Reichardt P, Schöffski P, Trent JC.

Oncologist. 2015 Jul;20(7):823-30. doi: 10.1634/theoncologist.2014-0471. Epub 2015 Jun 12. Review.

PMID:
26070915
7.

Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery.

Joensuu H, Martin-Broto J, Nishida T, Reichardt P, Schöffski P, Maki RG.

Eur J Cancer. 2015 Aug;51(12):1611-7. doi: 10.1016/j.ejca.2015.05.009. Epub 2015 May 25. Review.

8.

Cancer in young adults with ischemic stroke.

Aarnio K, Joensuu H, Haapaniemi E, Melkas S, Kaste M, Tatlisumak T, Putaala J.

Stroke. 2015 Jun;46(6):1601-6. doi: 10.1161/STROKEAHA.115.008694. Epub 2015 Apr 28.

PMID:
25922510
9.

Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib.

Lee CK, Goldstein D, Gibbs E, Joensuu H, Zalcberg J, Verweij J, Casali PG, Maki RG, Cioffi A, Mcarthur G, Lord SJ, Yip D, Kanjanapan Y, Rutkowski P.

Eur J Cancer. 2015 May;51(7):852-60. doi: 10.1016/j.ejca.2015.02.015. Epub 2015 Mar 19.

PMID:
25801699
10.

Elevated levels of StAR-related lipid transfer protein 3 alter cholesterol balance and adhesiveness of breast cancer cells: potential mechanisms contributing to progression of HER2-positive breast cancers.

Vassilev B, Sihto H, Li S, Hölttä-Vuori M, Ilola J, Lundin J, Isola J, Kellokumpu-Lehtinen PL, Joensuu H, Ikonen E.

Am J Pathol. 2015 Apr;185(4):987-1000. doi: 10.1016/j.ajpath.2014.12.018. Epub 2015 Feb 12.

PMID:
25681734
11.

KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence.

Joensuu H, Rutkowski P, Nishida T, Steigen SE, Brabec P, Plank L, Nilsson B, Braconi C, Bordoni A, Magnusson MK, Sufliarsky J, Federico M, Jonasson JG, Hostein I, Bringuier PP, Emile JF.

J Clin Oncol. 2015 Feb 20;33(6):634-42. doi: 10.1200/JCO.2014.57.4970. Epub 2015 Jan 20.

PMID:
25605837
12.

Increased stomach cancer risk following radiotherapy for testicular cancer.

Hauptmann M, Fossa SD, Stovall M, van Leeuwen FE, Johannesen TB, Rajaraman P, Gilbert ES, Smith SA, Weathers RE, Aleman BM, Andersson M, Curtis RE, Dores GM, Fraumeni JF, Hall P, Holowaty EJ, Joensuu H, Kaijser M, Kleinerman RA, Langmark F, Lynch CF, Pukkala E, Storm HH, Vaalavirta L, van den Belt-Dusebout AW, Travis LB, Morton LM.

Br J Cancer. 2015 Jan 6;112(1):44-51. doi: 10.1038/bjc.2014.552. Epub 2014 Nov 4.

PMID:
25349972
13.

Voice quality after treatment of early vocal cord cancer: a randomized trial comparing laser surgery with radiation therapy.

Aaltonen LM, Rautiainen N, Sellman J, Saarilahti K, Mäkitie A, Rihkanen H, Laranne J, Kleemola L, Wigren T, Sala E, Lindholm P, Grenman R, Joensuu H.

Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):255-60. doi: 10.1016/j.ijrobp.2014.06.032.

PMID:
25304787
14.

Early pregnancy sex steroids and maternal breast cancer: a nested case-control study.

Fortner RT, Schock H, Kaaks R, Lehtinen M, Pukkala E, Lakso HÅ, Tanner M, Kallio R, Joensuu H, Grankvist K, Zeleniuch-Jacquotte A, Toniolo P, Lundin E, Surcel HM.

Cancer Res. 2014 Dec 1;74(23):6958-67. doi: 10.1158/0008-5472.CAN-14-2150. Epub 2014 Oct 3.

PMID:
25281720
15.

Risk of esophageal cancer following radiotherapy for Hodgkin lymphoma.

Morton LM, Gilbert ES, Stovall M, van Leeuwen FE, Dores GM, Lynch CF, Hall P, Smith SA, Weathers RE, Storm HH, Hodgson DC, Kleinerman RA, Joensuu H, Johannesen TB, Andersson M, Holowaty EJ, Kaijser M, Pukkala E, Vaalavirta L, Fossa SD, Langmark F, Travis LB, Lamart S, Simon SL, Fraumeni JF Jr, Aleman BM, Curtis RE.

Haematologica. 2014 Oct;99(10):e193-6. doi: 10.3324/haematol.2014.108258. No abstract available.

16.

Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.

Rautiola J, Donskov F, Peltola K, Joensuu H, Bono P.

BJU Int. 2014 Sep 23. doi: 10.1111/bju.12940. [Epub ahead of print]

PMID:
25252180
17.

Pancreatic cancer risk after treatment of Hodgkin lymphoma.

Dores GM, Curtis RE, van Leeuwen FE, Stovall M, Hall P, Lynch CF, Smith SA, Weathers RE, Storm HH, Hodgson DC, Kleinerman RA, Joensuu H, Johannesen TB, Andersson M, Holowaty EJ, Kaijser M, Pukkala E, Vaalavirta L, Fossa SD, Langmark F, Travis LB, Fraumeni JF Jr, Aleman BM, Morton LM, Gilbert ES.

Ann Oncol. 2014 Oct;25(10):2073-9. doi: 10.1093/annonc/mdu287. Epub 2014 Jul 25.

PMID:
25185241
18.

Dual targeting of HER2 with lapatinib and trastuzumab.

Joensuu H.

Lancet Oncol. 2014 Sep;15(10):1050-2. doi: 10.1016/S1470-2045(14)70342-0. Epub 2014 Aug 14. No abstract available.

PMID:
25130997
19.

ERBB4 promoter polymorphism is associated with poor distant disease-free survival in high-risk early breast cancer.

Kurppa KJ, Rokavec M, Sundvall M, Kellokumpu-Lehtinen PL, Joensuu H, Brauch H, Elenius K.

PLoS One. 2014 Jul 18;9(7):e102388. doi: 10.1371/journal.pone.0102388. eCollection 2014.

20.

Trastuzumab emtansine: mechanisms of action and drug resistance.

Barok M, Joensuu H, Isola J.

Breast Cancer Res. 2014 Mar 5;16(2):209. doi: 10.1186/bcr3621. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk